u/Buddah_Chillz420

The author claims "Psychedelics getting Trump sign off," implying favorable regulatory changes. If regulatory approval accelerates, companies like ATAI (Atai Life Sciences) working on psychedelic therapies could see increased investor interest and valuation. The author is holding and believes the uptrend will continue, making it a long opportunity based on policy sentiment. The post provides zero evidence; political news may be misinterpreted or irrelevant. Regulatory paths are long and uncertain. Stock is highly volatile and speculative.

Compass Pathways (CMPS) is listed as one of the author's holdings poised to benefit from accelerated psychedelic therapy approvals. The author's logic is that sector-wide positive news will lift all boats in the psychedelic biotech space. A generic long bet on the sector, tied to a vague political headline. CMPS has its own clinical trial risks. The post's catalyst is not specific to CMPS. Stock performance may not correlate with political news.